Skip to main content

HOPA Abstracts

Choice of Antifungal Prophylaxis and Risk for Invasive Fungal Disease in Patients With Acute Leukemia Receiving Oral Anticancer Therapies With Significant CYP450 Drug Interactions
Abstract #LB04
Matthew Yacobucci, PharmD, BCOP; Zhenzi Hong; Colby Webster; Alexis Gregoire; Ejemen Aigbedion
Read More
Evaluation of Fam-Trastuzumab Deruxtecan Utilization Among Patients With Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Abstract #LB05
Matt Arango, PharmD, BCOP; Hiba Alzouby, PharmD, BCOP; Ning Jin, MD; Ashish Manne, MBBS; Arjun Mittra, MD; Anne Noonan, MB ChB, PhD
Read More
Role of CYP2D6 Phenotypes in Doxorubicin-Related Cardiotoxicity
Abstract #LB06
Oksana O. Karpenko, PharmD, RPh, BCPS; Jodi L. Taraba, PharmD, MS, RPh, BCOP; Ross A. Dierkhising, MS; Kristin C. Cole, MS; Corina J. Doleski, PharmD, RPh, BCOP; Karthik V. Giridhar, MD, et al.
Read More
Implementation of an Oral Oncolytic Monitoring Pilot Program: A Specialty Pharmacist–Led Approach Using the Revised Edmonton Symptom Assessment System
Abstract #LB07
Clarissa Wilkins, PharmD, BCOP; Alexandra Ritenour, PharmD, CSP
Read More
Pressurized Intraperitoneal Aerosolized Chemotherapy: Operationalizing From a Pharmacy Perspective at a Large Academic Medical Center
Abstract #LB08
Aimee Merkert, PharmD; Megan Hinton, PharmD
Read More
Assessing Student Pharmacists’ Knowledge and Perceptions of Financial Toxicity Concepts Introduced in an Oncology Pharmacotherapy Course
Abstract #CR01
Charles Wight, PharmD; Matthew DellaVecchia, PhD; Nicholas Chow, PharmD, BCOP; Monica Tadros, PharmD, BCPS, BCOP
Read More
Biodistribution and Shedding Analysis Following RP1 Oncolytic Immunotherapy Dosing in Patients From the IGNYTE Clinical Trial: Implications for Oncology Pharmacists
Abstract #CR02
Christina Davis, PharmD, BCOP; Praveen K. Bommareddy, PhD, BPharm, MS; Alina Monteagudo, PhD; Mohammed M. Milhem, MD; Joseph J. Sacco, MD; Tawnya Lynn Bowles, MD, et al.
Read More
Characterizing Second-Line and Beyond Treatments for Primary Central Nervous System Lymphomas
Abstract #CR03
Erin K. Yeung, PharmD, BCPS, BCOP; Brian Primeaux, PharmD, BCOP; Chelsea Luo, PharmD, BCOP; Caitlin Linger, PharmD, BCOP; Sheree Chen, PharmD, BCOP; Bryan Do, PharmD, BCOP
Read More
Coordinating Better Outcomes in Multiple Myeloma: An Educational Initiative to Elevate Pharmacist Leadership in Novel Antibodies and CAR-T Therapy
Abstract #CR04
Jeffrey Murray, PharmD, PVI; Carmine DeLuca; Michael Beyer, PVI; Zahra Mahmoudjafari, PharmD; R. Donald Harvey, PharmD
Read More
Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients in the United States (DEAR): Comparative Real-World Evidence
Abstract #CR05
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Alicia K. Morgans, MD; Neal D. Shore, MD; Nasreen Khan, PhD; Niculae Constantinovici, MD; Javeed Khan, MSc, et al.
Read More
Page 6 of 15
Results 51 - 60 of 146